MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced its participation as a Sponsor and Exhibitor at the 9th Annual MASH-TAG 2025 Conference, scheduled for January 9-11 at the Chateaux Deer Valley in Park City, Utah. This announcement follows the company's recent disclosure of positive top-line 16-week results from their Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The company's management and clinical team will be present at the conference's Exhibit Hall to discuss the trial results.

Positive

• Positive top-line results achieved in Phase 2a trial of DA-1241
• Successfully completed 16-week clinical trial period

Negative

• None.

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9^th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-the-9th-annual-mash-tag-2025-conference-after-releasing-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241-in-patients-with-presumed-mash-302335535.html

SOURCE MetaVia Inc.

FAQ

What were the results of MetaVia's (MTVA) Phase 2a trial for DA-1241?

MetaVia reported positive top-line results from their 16-week Phase 2a clinical trial of DA-1241 in patients with presumed MASH, though specific details of the results were not disclosed in the announcement.

When will MetaVia (MTVA) present at the MASH-TAG 2025 Conference?

MetaVia will participate in the MASH-TAG 2025 Conference from January 9-11, 2025, at the Chateaux Deer Valley in Park City, Utah.

What is the mechanism of action for MetaVia's (MTVA) DA-1241 drug?

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for patients with metabolic dysfunction-associated steatohepatitis (MASH).

What is MetaVia's (MTVA) role at the MASH-TAG 2025 Conference?

MetaVia will participate as a Sponsor and Exhibitor at the conference, with management and clinical team members available in the Exhibit Hall to discuss Phase 2a trial results.